Cargando…

The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States

BACKGROUND: Fibromyalgia (FM) is characterized by chronic, widespread pain, fatigue, and other symptoms; yet few studies have comprehensively assessed its humanistic burden. This observational study evaluates the impact of FM severity on patients' symptoms, health-related quality of life (HRQoL...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Caroline, Chandran, Arthi, Hufstader, Meghan, Baik, Rebecca, McNett, Michael, Goldenberg, Don, Gerwin, Robert, Zlateva, Gergana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179696/
https://www.ncbi.nlm.nih.gov/pubmed/21859448
http://dx.doi.org/10.1186/1477-7525-9-71
_version_ 1782212541684908032
author Schaefer, Caroline
Chandran, Arthi
Hufstader, Meghan
Baik, Rebecca
McNett, Michael
Goldenberg, Don
Gerwin, Robert
Zlateva, Gergana
author_facet Schaefer, Caroline
Chandran, Arthi
Hufstader, Meghan
Baik, Rebecca
McNett, Michael
Goldenberg, Don
Gerwin, Robert
Zlateva, Gergana
author_sort Schaefer, Caroline
collection PubMed
description BACKGROUND: Fibromyalgia (FM) is characterized by chronic, widespread pain, fatigue, and other symptoms; yet few studies have comprehensively assessed its humanistic burden. This observational study evaluates the impact of FM severity on patients' symptoms, health-related quality of life (HRQoL), and productivity in the United States. METHODS: 203 FM subjects were recruited from 20 physician offices. Subjects completed a questionnaire including the EuroQol 5D (EQ-5D), Fibromyalgia Impact Questionnaire (FIQ), Multidimensional Assessment of Fatigue (MAF), Medical Outcomes Study Sleep Scale (MOS-SS), and Hospital Anxiety and Depression Scale (HADS) and questions about demographics, pain and other symptoms, HRQoL and productivity. FIQ total scores were used to define FM severity, with 0- < 39, 39- < 59, and 59-100, representing mild, moderate, and severe FM, respectively. Sites recorded subjects' clinical characteristics and FM treatment on case report forms using medical records. Summary statistics were calculated for continuous variables and frequency distributions for categorical variables. Differences across FM severity groups were evaluated using the Kruskal-Wallis or Chi-square tests. Statistical significance was evaluated at the 0.05 level. RESULTS: Mean (SD) age was 47.9 (10.9); 95% were female. Most (92%) were prescribed medication for FM; 24% and 66% reported moderate and severe FM, respectively. Mean (SD) scores were: 6.3 (2.1) for pain intensity; 0.35 (0.35) for EQ-5D; 30.7 (14.2) for MAF; 57.5 (18.4) for MOS-SS Sleep Problems Index; 10.2 (4.8) for HADS anxiety and 9.4 (4.4) for HADS depression. Subjects with worse FM severity reported significantly increased pain severity, HRQoL, fatigue, sleep disturbance, anxiety and depression (p < 0.001). Overall, 50% of subjects reported some disruption in their employment due to FM; this differed across severity levels (p < 0.001). Employed subjects missed a mean (SD) of 1.8 (3.9) workdays during the past 4 weeks; this also differed across severity levels (p = 0.03). CONCLUSIONS: FM imposes a substantial humanistic burden on patients in the United States, and leads to substantial productivity loss, despite treatment. This burden is higher among subjects with worse FM severity.
format Online
Article
Text
id pubmed-3179696
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31796962011-09-25 The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States Schaefer, Caroline Chandran, Arthi Hufstader, Meghan Baik, Rebecca McNett, Michael Goldenberg, Don Gerwin, Robert Zlateva, Gergana Health Qual Life Outcomes Research BACKGROUND: Fibromyalgia (FM) is characterized by chronic, widespread pain, fatigue, and other symptoms; yet few studies have comprehensively assessed its humanistic burden. This observational study evaluates the impact of FM severity on patients' symptoms, health-related quality of life (HRQoL), and productivity in the United States. METHODS: 203 FM subjects were recruited from 20 physician offices. Subjects completed a questionnaire including the EuroQol 5D (EQ-5D), Fibromyalgia Impact Questionnaire (FIQ), Multidimensional Assessment of Fatigue (MAF), Medical Outcomes Study Sleep Scale (MOS-SS), and Hospital Anxiety and Depression Scale (HADS) and questions about demographics, pain and other symptoms, HRQoL and productivity. FIQ total scores were used to define FM severity, with 0- < 39, 39- < 59, and 59-100, representing mild, moderate, and severe FM, respectively. Sites recorded subjects' clinical characteristics and FM treatment on case report forms using medical records. Summary statistics were calculated for continuous variables and frequency distributions for categorical variables. Differences across FM severity groups were evaluated using the Kruskal-Wallis or Chi-square tests. Statistical significance was evaluated at the 0.05 level. RESULTS: Mean (SD) age was 47.9 (10.9); 95% were female. Most (92%) were prescribed medication for FM; 24% and 66% reported moderate and severe FM, respectively. Mean (SD) scores were: 6.3 (2.1) for pain intensity; 0.35 (0.35) for EQ-5D; 30.7 (14.2) for MAF; 57.5 (18.4) for MOS-SS Sleep Problems Index; 10.2 (4.8) for HADS anxiety and 9.4 (4.4) for HADS depression. Subjects with worse FM severity reported significantly increased pain severity, HRQoL, fatigue, sleep disturbance, anxiety and depression (p < 0.001). Overall, 50% of subjects reported some disruption in their employment due to FM; this differed across severity levels (p < 0.001). Employed subjects missed a mean (SD) of 1.8 (3.9) workdays during the past 4 weeks; this also differed across severity levels (p = 0.03). CONCLUSIONS: FM imposes a substantial humanistic burden on patients in the United States, and leads to substantial productivity loss, despite treatment. This burden is higher among subjects with worse FM severity. BioMed Central 2011-08-22 /pmc/articles/PMC3179696/ /pubmed/21859448 http://dx.doi.org/10.1186/1477-7525-9-71 Text en Copyright ©2011 Schaefer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Schaefer, Caroline
Chandran, Arthi
Hufstader, Meghan
Baik, Rebecca
McNett, Michael
Goldenberg, Don
Gerwin, Robert
Zlateva, Gergana
The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
title The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
title_full The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
title_fullStr The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
title_full_unstemmed The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
title_short The comparative burden of mild, moderate and severe Fibromyalgia: results from a cross-sectional survey in the United States
title_sort comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the united states
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179696/
https://www.ncbi.nlm.nih.gov/pubmed/21859448
http://dx.doi.org/10.1186/1477-7525-9-71
work_keys_str_mv AT schaefercaroline thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT chandranarthi thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT hufstadermeghan thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT baikrebecca thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT mcnettmichael thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT goldenbergdon thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT gerwinrobert thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT zlatevagergana thecomparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT schaefercaroline comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT chandranarthi comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT hufstadermeghan comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT baikrebecca comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT mcnettmichael comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT goldenbergdon comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT gerwinrobert comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates
AT zlatevagergana comparativeburdenofmildmoderateandseverefibromyalgiaresultsfromacrosssectionalsurveyintheunitedstates